0.9254

0.48% -0.0139

Bluejay Diagnostics Inc (BJDX)

Panoramica Notizia Cronologia dei prezzi Financials Perché BJDX Giù? Forum Previsione Frazionamento azionario

Precedente Chiudi:

$0.9393

Aprire:

$0.9277

Volume 24 ore:

13,991

Relative Volume:

0.00

Capitalizzazione di mercato:

$980.39K

Reddito:

Utile/perdita netta:

$-6.90M

Rapporto P/E:

-0.066

EPS:

-14.0152

Flusso di cassa netto:

$-6.65M

1 W Prestazione:

-10.97%

1M Prestazione:

-19.41%

6M Prestazione:

-53.72%

1 anno Prestazione:

-82.56%

Intervallo 1D:

$0.9259

$0.9475

Intervallo di 1 settimana:

$0.916

$1.0497

Portata 52W:

$0.83

$16.68

Bluejay Diagnostics Inc Stock (BJDX) Company Profile

Nome

Bluejay Diagnostics Inc

Settore

Healthcare (1083)

Industria

Medical Devices (140)

Telefono

(978) 631-0152

Indirizzo

360 MASSACHUSETTS AVENUE, SUITE 203, ACTON

Dipendente

Cinguettio

Prossima data di guadagno

2026-08-13

Ultimi documenti SEC

BJDX's Discussions on Twitter

Compare BJDX vs ABT, SYK, MDT, BSX, EW

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
BJDX Bluejay Diagnostics Inc	0.9475	993.43K	0	-6.90M	-6.65M	-14.02
ABT Abbott Laboratories	114.56	198.01B	46.59B	5.41B	7.38B	3.0938
SYK Stryker Corp	329.54	130.41B	25.27B	3.34B	4.57B	8.6334
MDT Medtronic Plc	92.21	120.48B	36.36B	4.84B	5.43B	3.7261
BSX Boston Scientific Corp	49.51	75.37B	20.62B	3.56B	3.48B	2.3847
EW Edwards Lifesciences Corp	89.43	53.19B	6.30B	1.07B	1.09B	1.8406

Bluejay Diagnostics Inc Borsa (BJDX) Ultime notizie

Aug 18, 2026

Bluejay (BJDX) Session-Level Review: Loses 4.90% to Close at $0.97 at the Close; Reference Levels: the Session Ends Within the Reported Technical Boundaries for the Current SessionGrowth ETF - Vinanet

Aug 18, 2026

Bluejay Diagnostics (BJDX) links director options to FDA nod - Stock Titan

Aug 18, 2026

Bluejay Diagnostics (BJDX) links director’s 100K options to FDA clearance - Stock Titan

Aug 18, 2026

Bluejay Diagnostics (BJDX) ties director’s options to FDA device clearance - Stock Titan

Aug 18, 2026

Bluejay Diagnostics (NASDAQ: BJDX) insider updates share holdings - Stock Titan

Aug 18, 2026

Bluejay Diagnostics (NASDAQ: BJDX) ties director options to FDA clearance - Stock Titan

Aug 18, 2026

Aug 14, 2026

Armistice Capital discloses 9.99% Bluejay Diagnostics (BJDX) position in Schedule 13G - Stock Titan

Aug 14, 2026

Aug 13, 2026

Bluejay Diagnostics (BJDX) investor group discloses 9.99% ownership with warrants - Stock Titan

Aug 13, 2026

Form 8K Bluejay Diagnostics Inc For: 13 August By Investing.com - Investing.com Nigeria

Aug 13, 2026

Bluejay Advances Symphony Platform, Strengthens Cash Position - TipRanks

Aug 13, 2026

Form 8K Bluejay Diagnostics Inc For: 13 August - Investing.com India

Aug 13, 2026

Bluejay Diagnostics Q2 Results: EPS loss narrows 80% YoY to $(1.12) - scanx.trade

Aug 13, 2026

Bluejay Diagnostics completes enrollment in sepsis test study - Investing.com

Aug 13, 2026

Bluejay Diagnostics completes enrollment in sepsis test study By Investing.com - Investing.com Australia

Aug 13, 2026

Bluejay Diagnostics Completes Enrollment in SYMON-II Pivotal Study, Advances Toward 510(k) Submission and Commercialization - quiverquant.com

Aug 13, 2026

Bluejay completes 750-patient study enrollment for Symphony IL-6 - Stock Titan

Aug 13, 2026

Aug 12, 2026

Bluejay Diagnostics, Inc. Q2 2026: Net loss $(2.32M), EPS $(1.12) — 10-Q Summary - TradingView

Aug 12, 2026

Bluejay Diagnostics (BJDX) warns on going concern and Nasdaq listing risk - Stock Titan

Aug 12, 2026

Aug 07, 2026